Thallion reports data on cancer-killing TLN-4601
November 19, 2009 by leonardzehr · Leave a Comment
Thallion Pharmaceuticals (TSX:TLN) presented non-clinical data on TLN-4601, a proprietary small molecule with the potential to treat multiple tumour types, at cancer therapeutics conference in Boston. “These results highlight the ability of TLN-4601 to rapidly induce cell death in a hematologic tumour cell line and expand our understanding of TLN-4601 beyond its inhibition of the [...]
Listen to BioTuesdays 
